Physician profile
Michael O Crews
NPI 1215915137
$2,087.72
in general payments reported to CMS, 2019-2025
23 companies · $199 in 2025
The $199 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2020: $280 · 2021: $348 · 2022: $489 · 2023: $215 · 2024: $244 · 2025: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $658.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $658.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $389.35 | 2021-2025 | |
| Novo Nordisk INC | $272.26 | 2019-2024 | Wegovy, Ozempic |
| Astrazeneca Pharmaceuticals LP | $203.99 | 2020-2025 | Breztri, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $184.29 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $158.29 | 2019-2020 | |
| Allergan, INC. | $137.21 | 2019-2020 | |
| Pfizer INC. | $102.14 | 2019-2025 | |
| Lilly USA, LLC | $84.61 | 2019-2024 | Zepbound |
| Exact Sciences Corporation | $82.66 | 2023-2025 | Cologuard Collection Kit |
| Vanda Pharmaceuticals INC. | $82.41 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $58.97 | 2021-2022 | |
| Alkermes, INC. | $54.53 | 2023-2024 | Lybalvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.04 | 2019-2021 | |
| Amarin Pharma, INC. | $38.58 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $32.51 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $31.79 | 2024 | Yupelri |
| Axsome Therapeutics, INC. | $23.46 | 2024 | Auvelity |
| Abbott Laboratories | $20.46 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.12 | 2023 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.91 | 2024 | Caplyta |
| Genentech USA, INC. | $15.76 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $14.29 | 2019 | |
| Amgen INC. | $12.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Crews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.